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Abstract
New multifunctional drugs that target multiple disease-relevant networks offer a novel approach to the prevention and
treatment of many diseases. New synthetic oleanane triterpenoids (SO), such as CDDO (2-cyano-3,12-dioxooleana-1,9-dien-
28-oic acid) and its derivatives, are multifunctional compounds originally developed for the prevention and treatment of
inflammation and oxidative stress. However, the protein binding partners and mechanisms of action of these SO are not yet
fully understood. Here we characterize the putative target profile of one SO, CDDO-Imidazolide (CDDO-Im), by combining
affinity purification with mass spectroscopic proteomic analysis to identify 577 candidate binding proteins in whole cells.
This SO pharmaco-interactome consists of a diverse but interconnected set of signaling networks; bioinformatic analysis of
the protein interactome identified canonical signaling pathways targeted by the SO, including retinoic acid receptor (RAR),
estrogen receptor (ER), insulin receptor (IR), janus kinase/signal transducers and activators of transcription (JAK/STAT), and
phosphatase and tensin homolog (PTEN). Pull-down studies then further validated a subset of the putative targets. In
addition, we now show for the first time that the mammalian target of rapamycin (mTOR) is a direct target of CDDO-Im. We
also show that CDDO-Im blocks insulin-induced activation of this pathway by binding to mTOR and inhibiting its kinase
activity. Our basic studies confirm that the SO, CDDO-Im, acts on a protein network to elicit its pharmacological activity.
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Introduction
Chronic diseases are now the prime cause of most pain and
suffering in American society, as well as the largest financial burden
in the health care system [1]. Their present treatment is often
unsatisfactory. Multiple factors are now known to cause the
initiation, as well as drive the progression, of chronic neurodegen-
erative, inflammatory, cardiovascular, metabolic, or neoplastic
diseases [2–4]. Because of the intrinsic complexity of all of these
diseases, we now need an innovative therapeutic approach that uses
multifunctional pharmaceuticals to simultaneously target an array
of pathogenetically relevant pathways, each of which contributes to
disease progression [5]. Such ‘‘systems-based’’ therapeutics would
have the marked advantage of subverting drug-resistance, improv-
ing efficacy, and reducing adverse side effects [5–6].
Over the past decade a series of synthetic triterpenoids based on
the natural triterpenoid, oleanolic acid (OA) has been synthesized
[7–9]. These synthetic oleanane triterpenoids (SO) are multifunc-
tional and have antiproliferative[10–11],anti-angiogenic[12], anti-
diabetic [13], pro-apoptotic [14–20], anti-inflammatory [10,11,21–
23], and cytoprotective [24–25] activities. Furthermore, the SO
have been successfully used to prevent and treat many chronic
diseases in experimental animals, including cancer [10,26–29],
emphysema [30–31], macular degeneration [32], liver disease [33–
34], neurodegenerative diseases [35–36] and nephrotoxicity [37] in
both in vitro and in vivo models. The SO, CDDO-methyl ester
(CDDO-Me, Bardoxolone methyl) is currently in late-stage clinical
development for treatment of chronic kidney disease (diabetic
nephropathy) [73].
In the development of second generation OA derivatives, two
electrophilic Michael acceptor sites were incorporated in the A
and C rings of OA to increase the reactivity of OA toward cellular
targets [25,38]. In cells SO mediate their potent pharmacological
effects in part through interactions with cellular nucleophiles such
as discrete, redox-sensitive sulfhydryl groups of cysteine (Cys)
residues on proteins, via reversible Michael addition [7,9,25,38–
41]. Therefore, one may expect that SO should have many
cellular protein binding partners, depending on cellular context
and the nucleophilicity of specific cysteine residues in specific
targets.
A few biologically important targets of SO have already been
discovered. Activation of the KEAP1/Nrf2 pathway has been
shown to be critical for many of the activities of both CDDO-Me
and its close relative, CDDO-Imidazolide (CDDO-Im) [24,25,42].
However, the SO are known to modulate numerous pathways in
cell culture and recently it was shown that many KEAP1/Nrf2-
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administration of CDDO-Im in vivo [43]. To date, no global study
to identify the complete spectrum of binding partners of SO on a
proteome-wide scale has been reported. Therefore, here we report
the results of such a proteomics approach. We have utilized biotin
tagged SO conjugates as chemical probes to affinity purify protein
binding partners after treatment of cells in culture and have
identified these proteins by LC-MS/MS. We report here the
identification of 577 proteins to which a biotinylated probe binds.
This approach also identified and validated binding partners
which have previously been reported to be direct SO targets,
including IKK, JAK1, PTEN and tubulin [39,40,44–45]. Our
studies now show that the multi-functional SO, CDDO-Im, as
expected, exerts its varied pharmacological actions by acting on
large and diverse protein networks.
Materials and Methods
Reagents
CDDO-Im, TP-154 and TP-304 have been described previ-
ously [14,46–50], TP-304 is Compound 6 in Ref. 49. They were
dissolved in DMSO, and controls containing equal volumes of
DMSO (,0.1%) were included in all experiments. Sources of
commercial reagents were: rabbit polyclonal antibodies against
HO-1, Keap-1, tubulin and GAPDH, Santa Cruz Biotechnology;
all other antibodies were from Cell Signaling Technology. Insulin,
LY294002, Rapamycin and all other chemicals were obtained
from Sigma.
Cell Culture
HEK293 and PC-3 cells were from ATCC, and maintained in
DMEM (HEK293) or RPMI (PC-3), with 10% FBS and in 5%
CO2. In some cases cells were plated and treated in culture media
containing 1% horse serum. To measure proliferation, an MTT
assay was performed as described previously [45].
Cell Lysis, Western Blotting and mTORC1
Immunoprecipitation
For Western blots, HEK293 cells were washed twice with cold
PBS and suspended in RIPA buffer (25 mM Tris-HCl pH 7.6,
150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS,
1 mM sodium orthovanadate (Na3VO4), 1 mmol/L phenyl-
methylsulfonyl fluoride (PMSF), 10 mmol/L leupeptin, and
5 mg/ml aprotinin). Protein concentration in centrifuged lysates
was determined by Bradford assay. Lysates were immunoblotted
as described previously [39]. Blots were developed with either
pico-supersignal or femto-supersignal (Fisher Scientific). For
mTORC1 immunoprecipitation [51], cells were washed twice
with PBS and suspended in cold lysis buffer B (10 mM KPO4,
pH 7.2, 0.3% CHAPS (to preserve the mTOR-Raptor interac-
tion), 1 mM EDTA, 5 mM EGTA, 10 mM MgCl2, 50 mM beta-
glycerophosphate, 1 mM Na3VO4). Clarified lysate supernatants
were incubated with anti-RAPTOR polyclonal antibodies for 2 h
at 4uC, followed by incubation with protein A Sepharose beads for
2 h. Immunoprecipitates were washed three times in lysis buffer B,
and resuspended in 50 ml of Laemmli loading buffer followed by
immunoblotting with mTOR antibodies [52].
Biotinylated-Triterpenoid target affinity purification and
Gel Staining for Proteomics
HEK-293 cells were plated in DMEM with 1% horse serum.
The following day cells were treated with biotinylated SO as
indicated for 1 h. Cells were then washed twice with cold PBS and
lysed in Tris-HCl, 1% Triton X-100, pH 7.4 (Buffer A).
Centrifuged lysates were incubated with 50 ml of MyOne
TM
Streptavidin T1 paramagnetic DynabeadsH (Invitrogen Corpora-
tion, Carlsbad, CA) for 1 h. DynabeadH-biotinylated triterpenoid
protein-complexes were isolated magnetically and washed a total
of five times with buffer A. An additional sample was treated with
TP-304 and washed with a more stringent wash buffer (100 mM
TrisHCl pH 7.4, 150 mM NaCl, 1% (v/v) Triton X-100,
300 mM sodium actate, 0.1% (v/v) SDS) to disrupt protein
complexes and remove non-specific binding proteins. Complexes
were boiled in Laemmli loading buffer and separated on 4–20%
gradient, SDS-PAGE gels followed by staining overnight in a
solution of 50% MeOH, 40% H2O, 10% acetic acid and 0.125%
Coomassie brilliant blue R-250.
Sample preparation, MS and data anlysis
Coomassie-stained gels were divided into 8 regions and digested
with trypsin overnight at room temperature. The next day,
peptides were extracted, dried, and analyzed by nanoscale
microcapillary LC-MS/MS as described. Samples were loaded
using a FAMOS autosampler (LC Packings/Dionex, Sunnyvale
CA) onto a custom manufactured reverse-phase, Reprosil-Pur
3 mm, 200 A ˚ C18-AQ particle filled (Dr. Maisch GMBH,
Ammerbuch-Entringen, Germany) fritless-tip microcapillary col-
umns (0.1256180 mm, 7 mm tip) (Polymicro Technologies,
Phoenix, AZ, and Sutter Instruments, Novato, CA) using an
HPLC-driven (Agilent 1200 capLC) split-flow system designed to
maintain 1200–1500 psi at the head of the analytical column. The
resultant peptide eluate was directed into an LTQ-Orbitrap high
performance mass spectrometer operating in a data-dependent
sequencing acquisition mode across a 60-minute reverse-phase
gradient (5% acetonitrile / 0.1% formic acid to 30% acetonitrile /
0.1% formic acid). The collected tandem mass spectra were data-
searched using the SEQUEST algorithm [53], filtered to less than
1% false discovery rate using the target-decoy strategy [54] and
reported.
Pathway analysis
For Go annotation, UniProt IDs were submitted to GOR-
etriever [55] and categorized in GO_slim categories using
CateGOrizer [56]. Overall connectivity of identified proteins
was determined using STRING [57]. Highly connective subnet-
works in the STRING network were identified using MCODE
plug-in into Cytoscape [58]. For network analysis, UniProt IDs
were submitted to Ingenuity software (IngenuityH Systems, www.
Ingenuity.com).
Results
Functional validation of biotinylated SO conjugates
confirms their use as chemical probes
To identify candidate cellular targets of SO, biotinylated SO
(btSO) conjugates have been synthesized. The pharmacological
activity of these btSO was initially measured here by their ability
to inhibit cellular proliferation (Figures 1a, 1b). Biotinylated TP-
304 strongly inhibited proliferation of HEK293 cells, while TP-
154 was completely inactive in this assay (Figure 1b). Furthermore
we compared TP-154 and TP-304 with a potent, non-biotinylated,
SO, CDDO-Im. We examined their ability to inhibit the
activation of the NFkB pathway as induced by TNFa,b y
measuring their prevention of the degradation of IkBa
(Figure 1c). CDDO-Im, blocks IkBa degradation, indicating that
it prevents activation of the NFkB pathway (Figure 1c). Again,
these results are also seen with TP-304, whereas the inactive TP-
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304 and TP-154 were selected for use in subsequent proteomic
studies. TP-304 was used as a chemical probe to affinity purify
target proteins, whereas TP-154 was used as an inactive negative
control.
Proteomics analysis reveals multiple SO binding proteins
Utilizing TP-304 and TP-154 as probes, we developed and
optimized protocols to treat cells in culture for proteomic analysis.
Because of the electrophilic nature of the SO and their ability to
bind to redox active targets, it was important to ensure that the
Figure 1. Characterization of SO for chemical proteomic studies. (A) The chemical structures of the SO, CDDO-Im (TP-235), TP-154 (inactive)
and TP-304 (active). (B) TP-304 but not TP-154 inhibits the proliferation of HE293 cells. HEK293 cells were treated with either DMSO (control), TP-304
or TP-154 at the concentrations indicated for 48 h. Proliferation was assessed by MTT assay. (C) CDDO-Im and TP-304 but not TP-154 prevent the
TNFa-induced degradation of IkBa. HEK293 cells were treated with DMSO (control), CDDO-Im, TP-304 or TP-154 at the concentrations indicated for
1 h followed by treatment with 10 ng/ml TNFa. Lysates were immunoblotted with antibodies against IkBa or tubulin (loading control).
doi:10.1371/journal.pone.0022862.g001
Molecular Targets of Synthetic Triterpenoids
PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22862biotinylated probes interact with protein binding partners in their
natural environment where the context-dependent nucleophilicity
of -SH groups in cysteine residues is preserved. Following
treatment with TP-304 and TP-154, both at 4 mM, for 1 h,
HEK293 cells were lysed, and lysates were incubated with
Neutravidin-coated Dynabeads to affinity purify protein targets
(Figure 2a). Affinity purified proteins were separated on SDS-
PAGE gels and stained with Coomassie blue (Figure 2b). Bands
were excised, trypsinized and proteins identified by LC-MS/MS.
The collected tandem mass spectra were data-searched using the
SEQUEST algorithm [53] to identify target proteins. Following
MS detection, proteins found in the TP-154 control sample were
subtracted from proteins that were common to TP-304-treated
samples, in both the normal and increased stringency wash
conditions. (Figure 2a, 2b & 2c). 577 proteins common to both the
TP-304 normal wash and the TP-304 high stringency wash were
subjected to bioinformatic analysis (Figure 2c). A complete list of
binding proteins is detailed in Figure S1.
The putative SO targets were annotated using gene ontology
(GO) identifiers. For GO annotation, UniProt IDs were submitted
to GORetriever and categorized in GO_slim categories using
CateGOrizer. GO annotation based on molecular function
showed that catalytic activity, protein kinase activity, transcription
regulator activity, kinase activity and enzyme regulator activity
represented 75% of putative TP-304 targets (Figure 3a). GO
categorization of SO targets by biological process identified
metabolism, transcription, development, cell cycle, and signal
transduction to be the most prominent biological processes
targeted by TP-304 (Figure 3b). While TP-304 bound to a large
number of proteins, these proteins form a highly interconnected
network. This overall connectivity map (or interactome) was
established using the STRING database of known and predicted
protein interactions, including direct (physical) and indirect
(functional) associations (Figure 3c and 3d; high resolution images
Figures S2 and S3). Interestingly, analysis of the STRING, SO-
protein interaction network identified a subset of densely
connected regions representing molecular complexes of intercon-
nected sub-networks (Figure 3d). This sub-network contained
clusters enriched with proteins involved in cell-cycle/cell division,
meiosis/mitosis. This is not surprising given the potent anti-
proliferative activities of the SO. Interestingly, central to these
enriched clusters of proteins were a number of proteins that
represent common signal transduction pathways critical for cell-
cycle and cell division including PI3K/AKT/mTOR, JAK/
STAT and BCR-ABL (Figure 3d). These data correlate with the
findings from the gene ontology molecular function analysis which
highlighted proteins involved in catalytic, kinase and transcription
regulatory functions as being central targets of the SO in biological
Figure 2. Chemical proteomics studies for identification of SO targets. (A) Schematic representation. HEK293 cells were treated with
biotinylated SO compounds for 1 h in culture. Following cell lysis, target proteins were affinity purified with paramagnetic beads. Beads were washed
extensively 56and remaining proteins were eluted by boiling in Laemmli buffer. Proteins were separated by SDS-PAGE on 4–12% gradient gels. Gels
were stained with Coomassie stain overnight followed by destaining until background staining was clear. Corresponding regions from both TP-154
and TP-304 gels were excised, trypsinised and protein identified by LC-MS/MS. (B) Image of Coomassie-stained gel submitted for mass-spectroscopic
analysis. (C) Proteins identified in the TP-154 samples (control) were subtracted from the TP-304 treatment groups.
doi:10.1371/journal.pone.0022862.g002
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signal transduction (Figures 3a and 3b).
Thus we analyzed TP-304 targets using the Ingenuity software
program to identify specific canonical pathways within the TP-304
binding partner dataset. This analysis identified a large number of
canonical pathways targeted byTP-304 with very high significance
(Figure 3e). The top 40 pathways are displayed in Figure 3e. While
these analyses identified many new pathways with which CDDO-
Im interacts, they also confirmed pathways for which the SO have
previously been shown to modulate, including, janus kinase/signal
transducers and activators of transcription (JAK/STAT), phos-
phatase and tensin homolog (PTEN), and AMP kinase (AMPK).
Validation of a subset of putative SO target proteins
Next we determined the validity of the putative SO binding
partners identified in the above proteomics studies. We used
methods previously employed to identify IKK as an SO target.
HEK293 cells were treated with 4 mM TP-304 for 1 h, followed
by lysis and pull-down of TP-304-protein binding partners with
Neutravidin-coated agarose beads. Following a series of washes to
eliminate nonspecific binding, the remaining bound proteins were
eluted and separated by SDS-PAGE followed by Western blotting.
This was performed for a subset of proteins specifically identified
above (Figures 2c, 3) by LC-MS/MS. As shown in Figure 4, we
found that TP-304 bound specifically to 10 proteins, including
protein kinase A, catalytic unit alpha (PKA-Ca) and beta (PKA-
Cb), ataxia telangiectasia and rad3 related (ATR), ataxia
telangiectasia mutated (ATM), retinoid X receptor a (RXR-a),
mammalian target of rapamycin (mTOR), AMP-dependent
protein kinase (AMPK) (Figure 4); and IkB-kinase (IKK), c-Jun,
and STAT1 (data not shown). These results in Figure 4 validate
the MS approach taken in Figures 2 and 3 above.
Functional validation of putative SO targets confirms
mTOR as a direct SO target
The SO can bind to nucleophilic Cys residues on binding
partners through Michael addition. Therefore, we sought to
confirm that such binding had a functional effect on some of the
binding partners identified above. We interrogated the Ingenuity-
assigned canonical pathways to identify specific SO binding
partners which appear in multiple pathways, and reasoned that
proteins that appear in multiple canonical pathways may represent
critical SO target nodes. Thus, components of the PI3K/AKT/
mTOR pathway were highly enriched in our canonical dataset.
We used the highly potent CDDO analog, CDDO-Im for these
studies and found that it was a potent inhibitor of the
phosphorylation of insulin-stimulated ribosomal S6 (RS6) at serine
235/236 (S235/236). As can be seen in Figure 5A, this
phosphorylation of S235/236 is dose-dependently inhibited by
CDDO-Im with complete inhibition observed at 250 nM.
Importantly, the biotinylated SO, TP-304 also inhibited the
phosphorylation of RS6 S235/236 (data not shown). Similarly, a
second phosphorylation site on S6, serine 240/244 (S240/244)
was also inhibited by the CDDO-Im (Figure 5A and data not
shown). Levels of total RS6 remained unchanged upon SO
treatment. We observed similar inhibition of the translational
repressor protein 4E-BP1 at serine 37. As expected, these effects
on RS6 and 4E-BP1 were also observed upon treatment with the
mTOR inhibitor, rapamycin. Both 4E-BP1 and RS6 are critically
important regulators of mitogen-induced mRNA translation levels
in cells and are downstream targets of the phosphatidylinositol-3-
OH kinase (PI3K) signal-transduction cascade which also includes
the kinases AKT, mTOR and P70S6K [59].
Thus, based on the observed enrichment for this pathway from
our proteomics experiments and the observed inhibition of
phosphorylation of both RS6 and 4E-BP1, we then investigated
the effects of CDDO-Im on this pathway in greater detail in a
hierarchical manner, beginning with RS6 and 4E-BP1 and
Figure 3. Bioinformatic analysis of putative SO target proteins. Gene ontology analysis of the candidate SO targets. GO_slim, gene ontology
analysis of the candidate substrates was done with the CateGOrizer program. (A) SO target proteins, were annotated by molecular function.
Categories with more than 20 assigned proteins are shown. (B) The 577 putative SO target proteins, were assigned to biological processes. Proteins
for which no biological process could be assigned were omitted from this display. Categories with more than 20 assigned proteins are shown. (C)
Overall connectivity of identified proteins was determined using STRING (Search Tool for the Retrieval of Interacting Genes/Proteins). (D) Highly
connected sub-networks within the STRING network. Different line colors represent the types of evidence for each association, blue lines: direct
binding, pink lines: post-translational modification. (E) For canonical pathway analysis, UniProt IDs were analyzed with Ingenuity pathway software.
The top 40 most significant canonical signaling pathways from the Ingenuity canonical pathway library mapped to the SO target dataset are
displayed. Threshold bar shows cut-off point of significance P,0.05, 2log(P-value) of 1.3 as determined using a right-tailed Fisher’s exact test. High
resolution images of the STRING network and sub-network can be found in the supplementary information.
doi:10.1371/journal.pone.0022862.g003
Figure 4. Validation of putative SO targets identified by LC-
MS/MS. HE293 cells were treated with either DMSO (control) or 4 mM
TP-304 for 1 h, as indicated. TP-304 binding proteins were affinity
purified with NeutrAvidin resin. Proteins were separated by SDS-PAGE
and immunoblots performed with various antibodies targeted toward a
subset of proteins identified in the prior LC-MS/MS studies. Samples
from whole cell lysate for both treatment conditions were also
immunoblotted (lanes 1 and 2) to show that treatments had no effect
on total protein levels.
doi:10.1371/journal.pone.0022862.g004
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CDDO-Im is inhibitory. Since P70S6 induces RS6 phosphoryla-
tion we looked at the insulin-induced activation of this important
kinase. As expected, insulin rapidly induced phosphorylation of
threonine 389 (T389) on P70S6K (Figure 5a). However, as
observed with RS6 and 4E-BP1, CDDO-Im and rapamycin both
prevented this activation, indicating that the inhibitory effects of
the SO took place at a level above P70S6K activation. Since both
P70S6K and 4E-BP1 are directly regulated by mTOR, and since
mTOR and its binding partner, RAPTOR, were identified as
direct targets for the SO in our proteomics screen we next
examined whether the inhibitory effects of the SO on this pathway
were mediated by disrupting the kinase activity of mTOR itself.
To examine the effects on mTOR in more detail we conducted
an in-vitro mTOR activation assay which examines the phos-
phorylation levels of serine 2481 of mTOR [52]. Serine 2481 is an
autophosphorylation site for this kinase [52]. mTORC1 was
isolated by immunoprecipitating with anti-RAPTOR antibodies
using a CHAPS-based lysis buffer which retains the integrity of the
mTORC1 complex. Following immunoprecipitation, we immu-
noblotted with anti-mTOR S2481 antibodies to determine the
level of phosphorylation at this autophosphorylation site. As can
be seen in Figure 5b, in quiescent, serum-starved cells this site
remains unphosphorylated but is rapidly phosphorylated (within
15 min) in response to insulin. This insulin-induced autophospho-
rylation is completely blocked by both rapamycin and CDDO-Im.
Importantly, there was no effect on total mTOR levels
immunoprecipitated by either rapamycin or CDDO-Im indicating
that these treatments were not simply disrupting the mTOR-
RAPTOR interaction. To further confirm the inhibition of
mTOR in this experiment we performed Western blot experi-
ments on whole cell lysates looking at phospho-P70S6K T389. As
can be seen in Figure 5b, both rapamycin and CDDO-Im
completely blocked autophosphorylation of P70S6K T389.
In order to exclude the possibility that the CDDO-Im was
inactivating the pathway upstream of mTOR, and in turn
blocking its activation we examined the activity of the upstream
activating kinases, PI3K and AKT, by looking at phosphorylation
levels of their substrates, AKT and GSK3b, respectively. As
expected, we found that insulin rapidly phosphorylated AKT at
Figure 5. CDDO-Im inhibits the autokinase activity of mTOR. CDDO-Im inhibits the mTOR pathway in HEK293 cells. (A) HEK293 cells were
treated with rapamycin (R, 20 nM) CDDO-Im or TP-304 as indicated for 1 h. Then, cells were treated with 100 nM Insulin for 30 min. Cells were lysed
in RIPA buffer and Western immunoblotting was performed with the antibodies listed. (B) CDDO-Im inhibits the auto-kinase activity of mTOR. HEK293
cells were treated with DMSO, rapamycin (20 nM) or CDDO-Im (500 nM) for 2 h. Cells were then stimulated with 100 nM insulin for 15 min. Cells were
lysed, and lysates were immunoprecipitated with anti-RAPTOR antibodies and protein A beads. Immunoprecipitates were separated by SDS-PAGE
and membranes blotted with anti-phospho-mTOR serine 2481 antibodies (top panel). Membranes were stripped and re-probed with antibodies for
total-mTOR (second panel). Whole cell lysates were Western blotted with antibodies against phospho-p70, threonine 389 (third panel) and alpha
tubulin (bottom panel). (C) CDDO-Im inhibits the mTOR pathway in cancer cells. PC-3 cells were treated with 10 mM of the PI3K inhibitor, LY 294002
(LY) or, CDDO-Im (500 nM) for 1 h. Cells were lysed in RIPA buffer and Western immunoblotting was performed with the antibodies listed.
doi:10.1371/journal.pone.0022862.g005
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or rapamycin, indicating that the CDDO-Im was not blocking
activation of, or inhibiting PI3K, nor was it blocking activation of
the mTOR complex 2 (mTORC2) which has recently been shown
to phosphorylate AKT at S473. Again, these effects mimic that of
rapamycin, which, under acute treatment conditions is unable to
inhibit the activity of mTORC2. Furthermore, no effect was
observed on phosphorylation of serine 9 of GSK3a/b (data not
shown) indicating that activation or activity of AKT was not
impaired by either CDDO-Im or Rapamycin (Figure 5a).
To determine if this inhibition of the mTOR signaling pathway
was idiosyncratic to HEK293 cells we examined the effect of
CDDO-Im in the prostate cell line, PC-3. PC-3 cells have
constitutive activation of the PI3K/AKT/mTOR signaling axis
due to mutations in the lipid phosphatase, PTEN, which
dephosphorylates PI3K. In PC3 cells CDDO-Im inhibited the
phosphorylation of RS6 S235/236 and 4E-BP1 S65 (Figure 5c),
indicating the effects observed in the HEK293 cells were not
unique to a single cell line.
Discussion
Utilizing a novel, chemical proteomics approach, we have
identified 577 proteins which interact with the biotinylated SO,
TP-304, in cell culture. While some of these proteins had
previously been identified, to date, this is the first report of a
comprehensive and system-wide analysis of SO binding partners.
As expected, a large number of new binding partners were
identified, forming a large interconnected network of proteins that
interact with SO. Many of the canonical pathways previously
implicated as being targeted by SO, such as NFkB, JAK/STAT,
PTEN and AMPK were found in this analysis [7,32,39,40,60–61].
In addition to these networks identified in silico, we have
functionally validated the mTOR pathway as a target for CDDO-
Im. Previous studies have suggested that this pathway may be
inhibited by very high concentrations of the SO, CDDO-Me [62–
63]. However, this is the first report to show that CDDO-Im also
inhibits this pathway and also the first report that nanomolar
concentrations of an SO directly inhibit the kinase activity of
mTOR. mTOR belongs to a family of 6 kinases referred to as
phosphoinositide-3-OH-kinase-related kinases (PIKKs). Interest-
ingly the PIKK family members ATM and ATR and TRRAP
were also pulled-down by TP-304.
The SO are extremely potent inhibitors of cellular proliferation
[10–11]. The concentrations at which such inhibition is observed
correlates with those we report for mTOR inhibition. Therefore,
one may propose that this potent inhibition of proliferation may,
in part, be due to inhibition of translation through disrupting
mTOR activity. The identification of the PI3K/mTOR pathway
as a central node in the STRING analysis interconnecting critical
cell cycle and cell division proteins as well as the prominence of
cell cycle proteins in the GO analysis would suggest this may be an
important target for the SO. Also, it was recently reported that
CDDO-Im alters microtubule dynamics by disrupting the
microtubule-capping protein, Clip-170 which is an mTOR target
protein [64]. Our observations suggest that the mechanism by
which CDDO-Im disrupts Clip-170 may be through inhibition of
the kinase activity of mTOR. Aberrant activation of mTOR and
S6K has been shown to play a critical role in the development of
diabetes and diabetic nephropathy [65–68]. Currently, CDDO-
Me (Bardoxolone methyl) is undergoing late stage clinical
development for the treatment of nephropathy in diabetes patients
and significant improvements in markers of renal function have
been reported [73]. Some of the improvements observed in these
patients may be mediated through the inhibition of the mTOR/
S6K signaling axis. Further studies toward this goal are ongoing in
our laboratory.
One caveat of our proteomics-based target search is its
qualitative nature, which lacks quantitative information about
the SO-target interaction. Binding in such assays is a function of
both protein/target abundance and affinity; therefore, highly
abundant-low affinity proteins will co-purify with low abundance
high-affinity proteins, making it difficult to infer relative affinities
of the SO for the identified targets. However, multi-functional
drugs typically bind to targets with lower affinity than a single
target drug. Previous studies have suggested that low-affinity,
multi-target drugs have a lower prevalence and a reduced range of
side-effects than high-affinity, single-target drugs while also being
more efficacious [7,69–71]. By virtue of their low affinity binding,
drugs of this type work best under pathological conditions, for the
prevention of disease by restoring cellular homeostasis. Indeed it is
in the area of chemoprevention that the SO have excelled in in vivo
models. Currently the development of network-based, multi-target
drugs similar in function to the SO is gaining increased interest in
the field of drug development [7,69–71]. Also, it should be noted
that not all 577 proteins identified by MS analysis may be direct
SO targets. It is possible that the lysis and wash conditions used did
not completely disrupt high affinity protein complexes. We
identified numerous proteins that are known to form high affinity
complexes in cells including, but not limited to ATM/ATR and
mTORC1. While this may cloud the identification of direct targets
it facilitates the identification of protein complexes and pathways
with which the SO interacts. One other caveat is the possibility
that the coupling of the biotin group on the btSO may impede
interactions with some target proteins. Indeed, TP-304 appears to
have a lower affinity for KEAP1 (unpublished observation) which
explains its absence from our list of proteins identified by MS.
However, in spite of the above caveats, the data shown here open
the way to new investigations that will examine the more difficult
problem of interactions of SO with targets in real time.
In summary, technological advances in the integration of
proteomics, pharmacology and molecular biology now provide the
means to map drugs and targets at a systems level. Indeed, it has
become evident that many drugs thought to specifically target a
single protein, e.g. the BCR-ABL inhibitors imatinib, nilotinib, and
dasatinib, are, in fact more promiscuous than originally thought
[72]. Further advances in drug development, enhanced by an
understanding of the genetic and epigenetic complexity of many
chronic diseases, will come from drugs that target multiple
components of critical signaling pathways and metabolic networks.
In this regard, our studies demonstrate the utility of proteomic
methods using biotinylated compounds as probes for identifying
new candidate targets and perhaps may facilitate the use of SO in
previously unrecognized therapeutic applications. The goals of
targeting complex networks and applying systems biology to drug
discovery are now of immediate importance.
Supporting Information
Figure S1 Complete list of protein TP-304 binding proteins
identified by LC-MS/MS. The collected tandem mass spectra
were data-searched using the SEQUEST algorithm, filtered to less
than 1% false discovery rate using the target-decoy strategy as
described in the materials and methods section. The list is
presented in descending order of total peptides (T.P.) and unique
peptides (U.P.)
(PDF)
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depicted in figure 3c.
(TIF)
Figure S3 High resolution, scalable image of the sub-network
map depicted in figure 3d.
(TIF)
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